Efficacy and Safety of Acarbose Chewable Tablets in Type 2 Diabetic Patients- randomized positive controlled double-blinded and double-dummy multicenter clinical trial

INTERVENTION: control group:acarbose 50mg (50mg each tablet) plus one dummy acarbose chewable tablet thrice daily ;experimental group:acarbose chewable tablet 50mg (50mg each tablet) plus one dummy acarbose tablet thrice daily ; CONDITION: type 2 diabetes mellitus PRIMARY OUTCOME: HbA1; SECONDARY OUTCOME: fasting and 2h blood glucose; INCLUSION CRITERIA: 1. type 2 diabetic patients; 2. patients aged 18‐70 years; 3. patients with a BMI of 19–35 kg/m2; 4. patients whose blood glucose was insufficiently controlled by sulphanylureas and/or metformin and who were on a stable dose for 4 weeks before the start of the study with a HbA1c level of 7–10% and FPG>=7.0mmol/l, 2hPPG>=11.1mmol/l.